Queen Mary Hospital is the first kidney transplant center in Hong Kong. Our first kidney transplant was performed in 1969. Apart from deceased donor kidney transplant, we also started live donor kidney transplantation services since 1983. Queen Mary Hospital is the only hospital providing multi-organ transplant service in Hong Kong. Our first combined kidney and liver transplantation was performed in 1994. In 2017, we performed the first ABO incompatible kidney transplant in Hong Kong.
Our kidney transplantation team has played leading role in the diagnosis and management of post-transplant infections. In the 80’s, we were the first centre that established anti-HCV assay (Nephrology in collaboration with Hepatology service) for the management of Hepatitis C infection in patients with kidney disease in Hong Kong. In the 90’s, we first established in Hong Kong the HBVDNA assay ( Nephrology service) for diagnosis and management of Hepatitis B infection in kidney transplant recipients. We have also first established the CMVpp65 antigenaemia assay (Nephrology in collaboration with Microbiology service) for diagnosis and management of Cytomegalovirus infection in transplant patients.
The Combined Renal Replacement Services of Queen Mary Hospital provides comprehensive care to patients with end stage kidney failure who need renal replacement therapy. Our multi-disciplinary team consisting of nephrologists, urologists, nurses, other professional and allied health staff that provide professional services to kidney transplant recipients and live kidney donors. These services include pre-transplantation assessment and long term management for kidney transplant recipients, and pre-donation suitability assessment and post-donation long term care for live kidney donor.
At the end of June 2017, our hospital has already performed over 600 kidney transplantation surgery and over 1000 patients have been under the care of our transplant team. We also actively engage in researches in the field of transplantation medicine to solicit ways to improve our care, reduce complications and enhance patient survival.
The first deceased donor kidney transplantation in Hong Kong took place in Queen Mary Hospital in 1969. We performed our first live donor kidney transplant in 1983. Our first combined kidney and liver transplantation was performed in 1994. In 2017, we performed the first ABO incompatible kidney transplant in Hong Kong.
NOW
1st ABO incompatible kidney transplantation
2017
500th kidney transplantation
2011
1st laparoscopic donor nephrectomy for live donor
2001
1st combined kidney liver transplant
1994
1st paediatrics kidney transplantation
1990
1st live donor (unrelated) kidney transplant
1988
100th kidney transplantation
1987
1st live donor (related) kidney transplantation
1983
1st deceased donor kidney transplant
1969
Between 1996 and June 2017, the overall 1-year, 3-year and 5-year patient survival rates were 97%, 93% and 91% respectively. For live donor kidney transplant, the patient survival rates were 98%, 98% and 98 % respectively. For deceased donor kidney transplant, the rates were 96%, 91% and 87% respectively.
97%
93%
91%
Prof. CHAN Daniel Tak Mao
(Division Chief)
Dr. CHOY Bo Ying Cindy
(Director of Combined Renal Replacement Services(Medical))
Prof. TANG Sydney Chi Wai
Dr. WANG Yee Moon Angela
Dr. YAP Desmond Yat Hin
Dr. MA Kam Man Maggie
Dr. CHAN Chi Wang Gary
Dr. KWAN Pui Yuen Lorraine
Dr. LUI Sing Leung
Dr. YIP Pok Siu Terence
Dr. MOK Ming Yee Maggie
Dr. TSU Hok Leung James
(Division Chief & Director of Combined Renal Replacement Services (Surgical))
Dr. MA Wai Kit
Dr. NG Tsui Lin Ada
Dr. HO Sze Ho Brian
Dr. LAM Pei Wayne
Dr. TSANG Chiu Fung
Dr. LAI Chun Ting Terence
Kidney transplant is the preferred treatment modality for most end stage renal failure (ESRF) patients. A kidney from a healthy person (usually a close relative) or a deceased cadaveric donor is transplanted to the patient under general anaesthesia. Prior to transplantation, the patient and the donor shall go through all the blood and urine tests and medical examinations. If transplantation is successful, the patient will no longer need to undergo dialysis treatment but must take life-long immunosuppressants to keep the body from rejecting the kidney.
It is important for patients to be compliant to the prescribed immunosuppressant in order to prevent rejection and maintain stable graft kidney function. Our doctors will monitor the drug level and review immunosuppressant regime regularly.
The commonly used immunosuppressants (anti-rejection medicine) are:
1. Prednisolone
2. Cyclosporin A
3. Tacrolimus
4. Mycophenolate Mofetil / Mycophenolate sodium
5. Azathioprine
6. m-TOR inhibitor(Sirolimus/Everolimus)
It is respectable to donate one of your kidneys to save your beloved. The relationship between the donor and recipient becomes even more intimate due to this act of love.
Kidney donation should be based on love and care, but not on any social pressure or financial reward.
If you want to donate kidney to your beloved, please express your donation wish to our medical staff. Our kidney transplant team will arrange counseling and assessment for you before deciding whether you are suitable kidney donor.
For further information on kidney donation and transplantation, please contact our medical staff or visit the related websites.
Renal Companion Association was established by a group of kidney transplant recipients in 1987 and is dedicated to improve the care and quality of life of kidney patients through education, advocacy and developing patient communities.
Contact
Telephone: 2794 3010
Fax: 2338 4820
Mail: PO BOX 20260, Hennessy Road Post Office, HK
Membership Application Form
瑪麗醫院為全港首個腎臟移植中心。全港首宗腎臟移植於1969年在本院進行。除了遺體腎移植,本院亦於1983年開始了活體腎臟移植服務。瑪麗醫院為全港唯一多器官移植中心。全港首宗肝腎移植於1994年於本院進行。此外,本院亦於2017年進行了本地首宗血型不相容腎臟移植。
我們一向致力改善對移植病人感染的治理。從八十年代開始,腎科與肝臟科合作創立了本港首個丙型肝炎病毒抗體檢測。其後於九十年代,腎科創立了本港首個乙型肝炎病毒DNA測試,為受感染乙型肝炎的移植病人作出檢測及治理。腎科亦與微生物科合作,創立本港首個巨細胞病毒(CMV) pp65抗原血癥檢測,為感染巨細胞病毒的移植病人作出檢測及治理。
我們的跨專科腎移植團隊包括腎科專科醫生,泌尿科專科醫生,護理以及其他專科和專職醫療人員。我們的腎臟移植專科服務包括為腎衰竭病人進行腎臟移植評估及術後治療,以及為活體腎捐贈者作捐贈手術前的身體評估和捐贈後的長期監察治療。
直至二零一七年六月底,瑪麗醫院已進行了超過600個腎臟移植手術,亦為1000多名腎移植病人提供覆診治療。除了臨床服務外,我們亦致力推動移植醫學的科學研究與教育,並應用科研成果於日常服務,以提升病人存活率及減少併發症。
全港首個腎臟移植於1969年在瑪麗醫院進行。 本院於1983年進行了首個活體腎臟移植。 全港首宗肝腎移植亦於1994年於本院進行。 此外,本院於2017年進行了本港首宗血型不相容腎臟移植。
現時
首例血型不相容腎臟移植
2017
第500宗腎臓移植
2011
首例腹腔鏡活體腎臓捐贈手術
2001
首例肝腎移植
1994
首例小兒活體腎臓移植
1990
首例活體腎臓移植(非血縁親屬)
1988
第100宗腎臓移植
1987
首例活體腎臓移植(血縁親屬)
1983
首例人體腎臓移植
1969
在1996至2017年6月期間,整體一年、三年、和五年的病人存活率分別是97%,93% 和91%。 活體腎臓移植的病人存活率分別是98%,98%和98%。 而遺體腎臓移植則分別是96%,91%和87%。
97%
93%
91%
腎臟移植,俗稱「換腎」,為大部份末期腎衰竭病者最理想的治療方式。病者需要接受全身麻醉手術,接受將一個由健康的人(通常是近親)或剛去逝病人所捐贈的健康腎臟移植到病者體內。在腎臟移植前,病者及近親都需作血液、尿液測試及身體檢查。 成功移植後的病者,不需再接受透析治療,但必須長期服用免疫抑制藥物,以防止排斥發生。
跟隨醫生指示服藥是預防排斥及維持移植腎功能穩定的最重要一環。我們的醫生團隊會定時監察藥物血濃度及調整抗排斥藥藥量。
下列是常用的抗排斥藥:
1.腎上腺激素(Prednisolone),俗稱「肥仔藥」
2. 環孢素(Cyclosporin A)
3. 普樂克復(Tacrolimus)
4. 驍悉/米芙(Mycophenolate Mofetil/ Mycophenolate sodium)
5. 硫唑嘌呤(Azathioprine)
6. 雷帕鳴/依維莫司(Rapamycin/ Everolimus)
捐贈自己的一個腎臟,以解救至愛親友的病痛,實為一偉大行為。捐贈者與接受者深切感受對方的關懷,相互關係更益密切。
唯此決定必須基於愛護,出自摯誠,不受任何社會壓力所影響,也不應從中獲取金錢或物質的回報。
如果閣下有意捐贈腎臟予親人,請約見我們醫護人員。腎臓移植組會為閣下進行一系列的健康狀況評估,也會轉介閣下到心理專家進行心理評估及輔導,以決定閣下是否適合捐出腎臟。
若想知道更多有關腎臟捐贈及移植的資科,可聯絡我們的醫護人員或瀏覽相關的網址。